Retinoic Acid Pathway Inhibition for Checkpoint-Resistant Sarcoma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for sarcomas, a rare but diverse group of mesenchymal malignancies, have limited efficacy, with five-year survival rates below 15% and immunotherapies like immune checkpoint blockers being ineffective in most patients.

Innovation Solution

The use of retinoic acid receptor inhibitors, retinoic X receptor inhibitors, or inhibitors of enzymes in the retinoic acid biosynthesis pathway, combined with immune checkpoint inhibitors and anti-IL13 antibodies, to modulate the tumor microenvironment and enhance anti-tumor immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune checkpoint blockers are used to treat sarcomas, then the treatment approach aligns with standard immunotherapy protocols, but the therapy is ineffective in the majority of patients

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidresponse rate across patient population

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the biochemical parameters of the tumor microenvironment by inhibiting retinoic acid biosynthesis pathway (using RALDH inhibitors) and retinoic acid signaling (using RAR/RXR inhibitors). This parameter change converts the immunosuppressive environment into an immunostimulatory one, enabling immune checkpoint blockers to become effective where they previously failed.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces intermediary compounds (retinoic acid pathway inhibitors) that mediate between the existing immune checkpoint blockers and the tumor microenvironment. These intermediaries modify the microenvironment to make it responsive to checkpoint inhibition, bridging the gap between current therapy and desired outcome.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If retinoic acid pathway inhibitors are added to immunotherapy regimen, then anti-tumor immune response is enhanced, but treatment complexity increases

Engineering Contradiction:

Improveimmunotherapy effectivenessVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges multiple therapeutic mechanisms into a unified treatment approach: retinoic acid biosynthesis inhibition (RALDH inhibitors), retinoic acid signaling inhibition (RAR/RXR inhibitors), and immune checkpoint blockade. This combination creates a synergistic effect where each component enhances the others, achieving greater efficacy than any single agent alone while managing complexity through rational drug selection.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20260014168A1Methods and Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy

Publication Date: 2026.01.15 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

AI summary

The present invention relates to compositions and methods comprising a retinoic acid receptor inhibitor, a retinoic X receptor inhibitor or an inhibitor of an enzyme in the retinoic acid biosynthesis pathway for treatment of a patient having a solid tumor. In some embodiments, the solid tumor is a sarcoma.